April 14, 2009
Phase 3 study of Provenge for advanced prostate cancerDendreon Corporation announced results from its Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study demonstrating that Provenge (sipuleucel-T) met its primary endpoint of improving overall survival compared to placebo control in men with advanced prostate cancer. The safety profile of Provenge appeared to be consistent with prior trials.
Provenge may represent the first product in a new class of active cellular immunotherapies (ACIs), uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer.
For more information call (206) 256-4545 or visit www.dendreon.com.